文献速递其他结缔组织病

血管扩张剂与小剂量阿司匹林降低系统性硬化症原发性心肌病变表现的发生率:DeSScipher起始队列研究

Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.
PubMed 文献 · Ann Rheum Dis · 2019-08-07

该研究纳入601例系统性硬化症患者,其中448例接受血管扩张剂治疗,153例未接受,随访0.5-4年。多变量Cox回归分析显示,血管扩张剂治疗与室性心律失常发生率降低相关(p=0.03),小剂量阿司匹林与心脏传导阻滞和/或Q波和/或起搏器植入发生率降低相关(p=0.02),活动性疾病与LVEF<55%和/或CHF及心脏传导阻滞和/或Q波和/或起搏器植入发生率升高相关(p=0.05)。

要点

  • 血管扩张剂治疗与室性心律失常发生率降低相关(p=0.03)。
  • 小剂量阿司匹林与心脏传导阻滞和/或Q波和/或起搏器植入发生率降低相关(p=0.02)。
  • 活动性疾病与LVEF<55%和/或CHF及心脏传导阻滞和/或Q波和/或起搏器植入发生率升高相关(p=0.05)。

核心结论

  • 血管扩张剂治疗和小剂量阿司匹林可能对系统性硬化症患者不同原发性心肌病变表现的发生具有预防作用。

主要发现

  • 随访914患者年期间,发生12例室性心律失常、5例Q波、40例心脏传导阻滞、6例起搏器植入、19例LVEF降低和/或充血性心力衰竭。
  • 多变量Cox回归分析显示,血管扩张剂治疗与室性心律失常发生率降低相关(p=0.03)。
  • 小剂量阿司匹林与心脏传导阻滞和/或Q波和/或起搏器植入发生率降低相关(p=0.02)。
  • 活动性疾病与LVEF<55%和/或充血性心力衰竭及心脏传导阻滞和/或Q波和/或起搏器植入发生率升高相关(p=0.05)。

临床怎么用

  • 在系统性硬化症患者中,可考虑使用血管扩张剂治疗以降低室性心律失常风险。
  • 小剂量阿司匹林可能用于降低心脏传导阻滞、Q波或起搏器植入的风险。
  • 对活动性疾病患者应加强监测LVEF和充血性心力衰竭及心脏传导阻滞等心肌病变表现。

局限性

  • 本研究为观察性队列研究,结果提示可能存在预防作用,但不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the influence of vasodilator drugs on the occurrence of features depending on myocardial ischaemia/fibrosis (ventricular arrhythmias, Q waves, cardiac blocks, pacemaker implantation, left ventricular ejection fraction (LVEF) <55%, and/or congestive heart failure and sudden cardiac death) in systemic sclerosis (SSc). METHODS: 601 patients with SSc were enrolled from 1 December 2012 to 30 November 2015 and had a second visit 0.5-4 years apart. 153 received no vasodilators; 448 received vasodilator therapy (ie, calcium channel blockers and/or ACE inhibitors or angiotensin II receptor blockers or combinations of them), 89 of them being also treated with either endothelin receptor antagonists or PDE5 inhibitors or prostanoids. Associations between the occurrence of myocardial disease manifestations and any demographic, disease and therapeutic aspect were investigated by Cox regression analysis. A Cox frailty survival model with centre of enrolment as random effect was performed. RESULTS: During 914 follow-up patient-years, 12 ventricular arrhythmias, 5 Q waves, 40 cardiac blocks, 6 pacemaker implantations and 19 reduced LVEF and/or congestive heart failure (CHF) occurred. In multivariate Cox regression analysis, vasodilator therapy was associated with a lower incidence of ventricular arrhythmias (p=0.03); low-dose acetylsalicylic acid (ASA) with a lower incidence of cardiac blocks and/or Q waves and/or pacemaker implantation (p=0.02); active disease with a higher incidence of LVEF <55% and/or CHF and cardiac blocks and/or Q waves and/or pacemaker implantation (p=0.05). CONCLUSIONS: The present study might suggest a preventative effect on the occurrence of distinct myocardial manifestations by vasodilator therapy and low-dose ASA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Valentini G, Huscher D, Riccardi A, et al. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis. 2019. PMID: 31391176. doi:10.1136/annrheumdis-2019-215486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。